In the high-stakes world of biotech and diagnostics, the “burn rate” is a constant shadow. To hit your next clinical milestone or scale your testing throughput, you need high-end instrumentation—Mass Specs, HPLCs, or fermentation platforms.
But here’s the dilemma: Do you spend your hard-earned venture capital on depreciating hardware, or do you take on debt?
Choosing between lab equipment debt financing and equity financing isn’t just a CFO’s task; it’s a strategic decision that affects your runway and your ownership.
Let’s break down the mechanics of lab equipment debt financing so you can keep your lab running and your equity intact.
What is Lab Equipment Debt Financing?
Lab equipment debt financing is a strategic tool that allows laboratories to acquire essential scientific tools—from ICP-OES to flow cytometers—without a massive upfront cash drain.
Lab equipment debt financing is commonly used by startups, established laboratories, and medical facilities looking to expand capacity without depleting their cash reserves
At Bold View Capital, we structure these deals to cover 100% of the costs, including the “soft costs” that banks often ignore, like delivery, installation, and calibration.
Terms typically range from 2 to 7 years, with the equipment itself serving as the primary collateral. It’s a predictable monthly line item that keeps your cash in the bank for R&D and payroll.
What is Lab Equipment Equity Financing?
Equity financing is the process of selling a “slice” of your company to investors (VCs, angels, or private equity) in exchange for a lump sum of capital.
While this cash can certainly buy a $500k LC/MS, it comes at a steep price: permanent dilution. You aren’t paying interest, but you are giving away a percentage of your future exit.
Key Financing Types & Features
Understanding the “flavor” of your lab equipment debt financing is critical to matching it with your lab’s workflow:
- Equipment Leasing (Operating Lease): Perfect for technology with high obsolescence rates. You get lower monthly payments and the flexibility to return, upgrade, or buy out the unit at Fair Market Value (FMV) at the end of the term.
- Equipment Financing (Capital Lease): Think of this as a “rent-to-own” model. You get immediate ownership benefits with a nominal purchase fee (like $1) at the end of the term.
- Sale-Leaseback: If you’ve already paid cash for your benchtop setup and realize you need that liquidity back, we buy the equipment from you and lease it back to you. It’s an instant infusion of non-dilutive capital.
Why Choose Lab Equipment Debt Financing?
For most scaling ventures, debt is the more efficient “fuel” for hardware.
- Cash Flow Optimization: Spread the cost of a Triple Quad across 60 months. This allows you to retain working capital for the things that actually drive valuation—like top-tier talent and clinical trials.
- Tax Advantages: In many jurisdictions, lease payments can be deducted as business expenses, lowering your overall tax liability.
- Avoid Obsolescence: Science moves fast. Leasing ensures you aren’t stuck with a decade-old analyzer when a more efficient model hits the market.
- Flexible Milestones: We can structure payments to match your reality—whether that’s a 90-day deferral while you wait for a grant or stepped payments that scale as your lab’s revenue grows.
The Reality of Equity Financing
Equity has its place, but using it for equipment is often the “most expensive” way to buy a microscope.
- No Repayment Required: There is no monthly bill, which is a relief for pre-revenue startups.
- Ownership Dilution: Every dollar of equity spent on a centrifuge is a dollar of your company you no longer own.
- High Cost of Capital: Investors expect a 10x return. If you use $500k of equity to buy gear, you’re effectively “paying” $5M for that equipment upon exit.
| Feature | Lab Equipment Debt Financing | Equity Financing |
| Ownership | 100% Retention. You keep your cap table clean and your equity for future milestones. | Dilution. You trade a permanent slice of your company for depreciating hardware. |
| Monthly Cost | Predictable OpEx. A fixed monthly payment that fits into your burn rate. | Zero. No monthly checks, which preserves immediate runway for pre-revenue labs. |
| Total Cost of Capital | Low. You pay interest, but it’s a finite, tax-deductible expense. | Extremely High. Investors expect a 10x return; that $500k instrument could “cost” $5M at exit. |
| Speed to Gear | Fast. We underwrite based on the asset and the science. We move at startup speed. | Slow. Months of due diligence, pitch decks, and legal hurdles. |
| Control | Complete. You run your lab your way. No board seats required. | Shared. Investors often demand board seats and a say in your strategic pivots. |
| Collateral | The Instrument. Usually, the equipment itself (e.g., the LC/MS or HPLC) secures the deal. | The Future. You are “collateralizing” the future potential of the entire enterprise. |
| Tax Impact | Advantageous. Payments are often deductible as a business expense. | None. Equity investments are not tax-deductible. |
Frequently Asked Questions
What is the downside of equity financing?
Beyond dilution, you lose control with equity financing. Investors often require board seats and have a say in your strategic direction. It’s also a grueling, months-long process compared to the speed of a lab equipment debt facility.
What are the benefits of equity financing?
Equity financing provides a “safety net.” Because there are no mandatory monthly payments, you don’t face the risk of default if a trial hits a snag or a grant is delayed.
Which is better, debt or equity financing?
It’s about the stage of the mission. Debt is superior for retaining ownership and lowering the long-term cost of capital if you have predictable (or pending) cash flow. Equity is better for high-risk, high-growth phases where you cannot afford any fixed monthly obligations.
How do I qualify for lab equipment debt financing?
We look at the whole picture. While we check credit scores and financial history (P&L, Balance Sheets), Bold View Capital also looks at your science. We understand the secondary market value of your LC/MS, which allows us to be more creative than a traditional bank.
The Bold View Capital Bottom Line
Don’t trade your cap table for a lab bench. If you know your GC from your GC/MS, you deserve a partner who does, too.
Ready to scale your science without the dilution? Contact Bold View Capital today.
